-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $6

Benzinga·03/02/2026 15:01:39
Listen to the news
Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and lowers the price target from $12 to $6.